At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
BIIB112biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)
In Brief
A Phase 2 clinical trial evaluating BIIB112 for X-Linked Retinitis Pigmentosa. Completed, enrolled 50 participants across 8 sites in 2 countries.
Detailed Summary
The objective of the study is to evaluate the safety, tolerability and efficacy of a single sub-retinal injection of BIIB112 in participants with X-linked retinitis pigmentosa (XLRP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsX-Linked Retinitis Pigmentosa
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedApr 2017
Primary CompletionNov 2020
TodayJul 2026
First PostedApr 14, 2017
Enrollment StartMar 8, 2017
Primary CompletionNov 18, 2020
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.2 years ago
Interventions
BIIB112biological
Administered as specified in the treatment arm.